Table 1 Select ongoing clinical trials for epidermal growth factor receptor tyrosine kinase inhibitors in the neoadjuvant setting

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Stage II NSCLC, Stage IIIA NSCLC

Erlotinib

NCT01470716

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage IIIA-N2 Non-small Cell Lung Cancer

EGFR-positive Non-Small Cell Lung Cancer

Icotinib

NCT03749213

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Stage I NSCLC

Stage IA NSCLC, Stage IB NSCLC, Stage II NSCLC

Stage IIA NSCLC

Stage IIB NSCLC

Stage IIIA NSCLC

Osimertinib

NCT03433469

Neoadjuvant Afatinib Therapy for Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Resectable EGFR positive stage III NSCLC

Afatinib

NCT04201756

Neoadjuvant Gefitinib followed by Surgery and Gefitinib In Unresectable Stage III NSCLC With EGFR Mutations

(NEGOTIATE)

Unresectable EGFR positive stage III NSCLC

Gefitinib

NCT02347839